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SHORT COMMUNICATION
Non-tuberculous mycobacteria (NTM) can affect a range 
of organs, leading to various clinical manifestations, in-
cluding lymphadenitis, dermatitis, and skeletal infection 
(1). In immunocompromised patients, NTM sometimes 
spread systemically via bacteraemia and may lead to 
fatal conditions, termed disseminated NTM infections 
(2). Mycobacterium  mantenii, which is a slow-growing 
mycobacteria, has been isolated, but its pathogenecity is 
largely unknown (3). 
Tocilizumab is an interleukin (IL)-6 receptor mono-
clonal antibody that inhibits signalling of IL-6, which 
plays a pivotal role in the pathogenesis of diseases such 
as rheumatoid arthritis and Castleman’s disease (4, 5). 
We report here a case of disseminated M. mantenii 
infection that emerged during treatment for Castleman’s 
disease, and was substantially aggravated by adminis-
tration of prednisolone and tocilizumab. 
CASE REPORT
A 70-year-old man was referred to our department for the eva-
luation of facial pustules and multiple subcutaneous nodules all 
over his body. The patient had a history of NTM infection; small 
lung nodules had been found 7 years previously, and mycobac-
terium culture from sputum was positive for M. scrofulaceum 
and M. paraffinicum. Since then, because the patient had been 
asymptomatic, he had been followed without medication. 
Three years later, the patient’s cervical and axillary lymph 
nodes became swollen and leg oedema developed. He had no 
fever, but his serum C-reactive protein (CRP) level increased to 
14.3 mg/dl (normal < 0.2 mg/dl). Computed tomography with 
fluorodeoxyglucose positron emission tomography (FDG-PET) 
revealed enlargement of multiple lymph nodes with increased 
accumulation of 18F-FDG. A biopsy of cervical lymph nodes 
revealed granulation tissue with inflammation and fibrosis, 
but was negative for Zeel-Nielsen stain and mycobacterium 
culture. Lymph node findings were not pathologically specific 
for Castleman’s disease, but based on the clinical findings and 
greatly elevated serum IL-6 level of 105 pg/ml (normal < 4.0 pg/
ml), the patient was diagnosed with Castleman’s disease. Pred-
nisolone was administered orally at a dose of 0.5 mg/kg/day. 
After treatment, the patient remained in a good clinical condi-
tion for approximately 3 years during prednisolone tapering, but 
oedema of the extremities and multiple reddish nodules with 
pruritus emerged on his face 6 months prior to this consultation, 
which spread to his trunk and extremities. Because Zeel-Nielsen 
staining of the nodules was negative for mycobacterium, they 
were considered to be an exacerbation of Castleman’s disease. 
In addition to oral prednisolone, 0.125 mg/kg/day, systemic 
tacrolimus, 1.5 mg/day/kg, was administered, but discontinued 
after 2 weeks because the facial papules enlarged and increased 
in number. Therefore intravenous tocilizumab, 480 mg/m2, 
every 2 weeks was added 3 months prior to this consultation. 
Subsequently, facial nodules formed pustules, which disinte-
grated into ulcerated lesions. The patient was referred to our 
department because of prominent aggravation of cutaneous 
manifestations. 
Physical examination revealed that multiple pustules ag-
gregated on the cheeks and nose, and some of them were 
ulcerated (Fig. 1a and b). In addition, red papules and pustu-
les were observed on the central area of the chest (Fig. 1c). 
Well-circumscribed, elastic-soft, asymptomatic subcutaneous 
nodules were present on the back and limbs. 
Skin biopsy was performed on the facial pustules, and his-
tology revealed that inflammatory cells, including lymphocy-
tes, neutrophils, and plasma cells, infiltrated markedly, with 
oedematous changes in the stromal tissue (Fig. 2). Increased 
capillary, epithelioid and multinucleated giant cells, forming 
non-necrotizing granulomas, were noted (Fig. 2a and b). Many 
acid-fast bacilli were visible with Zeel-Nielsen staining (Fig. 
2c), and M. mantenii was identified in mycobacterium culture. 
The patient subsequently presented with multiple nodules in 
the pharynx and paranasal sinuses, which eventually tested 
positive for mycobacterium by culture. 
NTM were also detected in culture of the lung, pharynx, and 
skin, and the patient was diagnosed as having a disseminated 
NTM infection during treatment for Castleman’s disease. To-
cilizumab was discontinued and prednisolone was decreased 
gradually to 0.2 mg/kg/day. Treatment with levofloxacin, 
rifampicin, ethambutol, and amikacin was administered. The 
pustules and erythematous papules disappeared and superficial 
ulcers with peripheral epithelization formed in approximately 
2 months. 
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Fig. 1. (a, b) Numerous aggregated ulcerated pustules on the cheeks and 
nose. (c) Erythematous papules and pustules on the central area of the chest.
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DISCUSSION
Patients with disseminated NTM infections are fre-
quently immunocompromised, e.g. individuals with 
acquired immune deficiency syndrome. In addition to 
the importance of interferon (IFN)-γ, IL-12, and tumor 
necrosis facter (TNF)-α in host defence against NTM 
infection, IL-17-producing T helper cells (Th17) cells 
have been reported to play an essential role in NTM 
infection-immunity (6). IL-6 promotes preferential dif-
ferentiation of Th17 in the condition of transforming 
growth factor (TGF)-β (7). Tocilizumab reduces IL-6 
pleiotropic actions on T-cell activation, antibody secre-
tion and Th17 differentiation, which may have contri-
buted to aggravation of the clinical manifestations of 
the skin lesions in this case (7).
The clinical appearance of skin lesions caused by 
NTM is diverse, and includes solitary nodules, ulcers, 
furuncles and abscesses (8). This patient had an accumu-
lation of pustules and red papules in seborrhoeic areas, 
as well as multiple subcutaneous nodules in which M. 
mantenii was detected. M. mantenii is a slow-growing, 
scotochromogenic mycobacteria, which was first isolated 
from 2 patients with chronic bronchitis in 2009 (3). M. 
mantenii is most closely related to M. scrofulaceum from 
the perspective of genetic, phenotypic and clinical data 
(3). Various kinds of NTM species are known to cause 
cutaneous diseases, but no reports have been found on M. 
mantenii as a cause of skin infection. M. scrofulaceum is 
rare cause of cutaneous infections (9), but disseminated 
M. scrofulaceum infections with multiple skin ulcers and 
abscesses have been reported in immunocompromised 
patients (10). Given that M. mantenii is similar to M. 
scrofulaceum, it can be assumed that M. mantenii might 
have spread hematogenously and formed multiple pustu-
les and subcutaneous nodules in immunosuppressive 
conditions caused by the administration of tocilizumab 
and long-term use of prednisolone. To our knowledge, 
this is the first report of skin lesions that may have been 
induced by infection with M. mantenii.
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Fig. 2. Pathological findings of facial pustules. 
(a) Formation of non-necrotizing granulomas. 
Scale bar: 100 µm. (b) Marked infiltration of 
inflammatory cells, consisting of plasma cells, 
neutrophils, lymphocytes, and histiocytes. 
Scale bar: 50 mm. (c) Zeel-Nielsen staining. 
Scale bar: 50 mm.
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